Leriglitazone Shows Benefits in Cell and Animal Models

Leriglitazone Shows Benefits in Cell and Animal Models

286047

Leriglitazone Shows Benefits in Cell and Animal Models

Leriglitazone, an oral treatment candidate for Friedreich’s ataxia (FA), can increase frataxin levels and reduce neuronal degeneration in cell and animal models of the disease, a study found. Along with promising clinical findings from a Phase 2 clinical trial (NCT03917225), the results support the use of leriglitazone, and the general strategy of activating PPAR gamma, as a treatment for FA. The study, “PPAR gamma agonist leriglitazone improves frataxin-loss impairments in cellular and animal models of Friedreich Ataxia,” was published in…

You must be logged in to read/download the full post.